TY - JOUR
T1 - Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
AU - Sirasanagandla, S. Rao
AU - Al-Huseini, Isehaq
AU - Sofin, R. G.Sumesh
AU - Das, Srijit
N1 - Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/7
Y1 - 2022/7
N2 - Bisphenol A (BPA) is an industrial ubiquitous compound, frequently used to produce synthetic polymers and epoxy resins. BPA is a well-recognized endocrine disruptor and xenoestrogen compound. Evidence from epidemiological and experimental studies suggests that perinatal BPA exposure (gestation and/or lactation) increases the risk of developing various diseases, including the cardiovascular system. Developmental programming refers to environmental insults during the critical window of development that affect the structure and physiology of body systems, causing permanent changes in later stages. BPA influences the developmental programming of non-communicable diseases in the offspring. In the present review, we discuss the developmental programming of cardiovascular diseases related to perinatal exposure to BPA, supported by epidemiological and experimental evidence from published literature. The majority of the reported studies found a positive association between perinatal BPA exposure and adverse cardiovascular repercussions in the fetal, neonatal, and adulthood stages. The possible underlying mechanisms include epigenetic modifications of genes involved in cardiac muscle development, autonomic tone, collagenous and non-collagenous extracellular matrix, cardiac remodeling and calcium homeostasis, and mitochondrial energy metabolism. Epigenetics can modify the outcome of any disease. Hence, in the present review, we also discuss the role of epigenetics in preventing cardiovascular diseases following perinatal exposure to BPA. We also highlight how future treatment and drug delivery related to cardiovascular involvement could be based on epigenetic markers.
AB - Bisphenol A (BPA) is an industrial ubiquitous compound, frequently used to produce synthetic polymers and epoxy resins. BPA is a well-recognized endocrine disruptor and xenoestrogen compound. Evidence from epidemiological and experimental studies suggests that perinatal BPA exposure (gestation and/or lactation) increases the risk of developing various diseases, including the cardiovascular system. Developmental programming refers to environmental insults during the critical window of development that affect the structure and physiology of body systems, causing permanent changes in later stages. BPA influences the developmental programming of non-communicable diseases in the offspring. In the present review, we discuss the developmental programming of cardiovascular diseases related to perinatal exposure to BPA, supported by epidemiological and experimental evidence from published literature. The majority of the reported studies found a positive association between perinatal BPA exposure and adverse cardiovascular repercussions in the fetal, neonatal, and adulthood stages. The possible underlying mechanisms include epigenetic modifications of genes involved in cardiac muscle development, autonomic tone, collagenous and non-collagenous extracellular matrix, cardiac remodeling and calcium homeostasis, and mitochondrial energy metabolism. Epigenetics can modify the outcome of any disease. Hence, in the present review, we also discuss the role of epigenetics in preventing cardiovascular diseases following perinatal exposure to BPA. We also highlight how future treatment and drug delivery related to cardiovascular involvement could be based on epigenetic markers.
KW - Bisphenol A
KW - bisphenol S
KW - cardiovascular system
KW - developmental programming
KW - epigenetics
KW - toxic
UR - http://www.scopus.com/inward/record.url?scp=85131527333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131527333&partnerID=8YFLogxK
U2 - 10.2174/0929867328666211206111835
DO - 10.2174/0929867328666211206111835
M3 - Review article
C2 - 34872473
AN - SCOPUS:85131527333
SN - 0929-8673
VL - 29
SP - 4235
EP - 4250
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
IS - 24
ER -